Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Metis TechBio Co., Ltd.

劑泰科技(北京)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 7666)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Metis TechBio Co., Ltd. (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcement of the Company dated June 5, 2026 in relation to the full exercise of the Over-allotment Option, the stabilizing actions and the end of the stabilization period (the "**Over-allotment Option Announcement**"). Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Over-allotment Option Announcement.

As disclosed in the Over-allotment Option Announcement, the Overall Coordinators, for themselves and on behalf of the International Underwriters, fully exercised the Over-allotment Option on June 5, 2026 in respect of an aggregate of 30,184,000 H Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The Over-allotment Shares will be allotted and issued by the Company at HK$10.50 per H Share, being the Offer Price per H Share under the Global Offering.

Following the full exercise of the Over-allotment Option, the total number of issued Shares of the Company will increase from 1,152,513,850 Shares to 1,182,697,850 Shares, and the registered capital of the Company will increase from RMB115,251,385 to RMB118,269,785.

In view of the above changes and pursuant to the authorization granted at the general meetings held on August 5, 2025 and April 22, 2026, the board of directors of the Company (the "**Board**") proposes to make certain amendments to the articles of association of the Company (the "**Articles of Association**") to reflect, among others, the change in the total number of issued Shares, the registered capital and the shareholding structure of the Company as a result of the full exercise of the Over-allotment Option.

Details of the proposed amendments to the Articles of Association are set out below:

Article 3, which originally read as:

On March 17, 2026, the Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the "**CSRC**") and was approved by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "**Hong Kong Stock Exchange**") to issue 201,229,000 ordinary shares to the public for the first time. All such ordinary shares were overseas listed foreign shares (hereinafter referred to as the "**H shares**"), which were listed on the Hong Kong Stock Exchange on May 13, 2026.

is amended as follows:

On March 17, 2026, the Company completed the filing with the China Securities Regulatory Commission (hereinafter referred to as the "**CSRC**") and was approved by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "**Hong Kong Stock Exchange**") to issue 201,229,000 ordinary shares (before the full exercise of the Over-allotment Option) to the public for the first time. All such ordinary shares were overseas listed foreign shares (hereinafter referred to as the "**H shares**"), which were listed on the Hong Kong Stock Exchange on May 13, 2026.

Article 6, which originally read as:

The registered capital of the Company is RMB115,251,385.

is amended as follows:

The registered capital of the Company is RMB118,269,785.

Article 20, which originally read as:

Upon the completion of the H share issuance, the total number of shares of the Company is 1,152,513,850 shares, and the shareholding structure of the Company shall be as follows: the total number of issued ordinary shares is 1,152,513,850 shares, of which 1,052,926,111 ordinary shares are overseas listed shares, representing 91.36% of the Company's total issued ordinary shares, and 99,587,739 ordinary shares are non-overseas listed shares, representing 8.64% of the Company's total issued ordinary shares.

is amended as follows:

Upon the completion of the H share issuance and the full exercise of the Over-allotment Option, the total number of shares of the Company is 1,182,697,850 shares, and the shareholding structure of the Company shall be as follows: the total number of issued ordinary shares is 1,182,697,850 shares, of which 1,083,110,111 ordinary shares are overseas listed shares, representing 91.58% of the Company's total issued ordinary shares, and 99,587,739 ordinary shares are non-overseas listed shares, representing 8.42% of the Company's total issued ordinary shares.

Article 210, which originally read as:

After the Articles of Association are deliberated and approved by the shareholders' general meeting, they shall take effect from the date of the Company's initial public offering and listing for trading on the Main Board of the Hong Kong Stock Exchange.

is amended as follows:

The Articles of Association shall become effective and be implemented from the date of approval by the shareholders' general meeting of the Company or from the date of consideration and approval by the Board and/or the authorized personnel by the Board authorized by the shareholders' meeting.

The industrial and commercial registration, filing and other matters in respect of the above amendments to the Articles of Association with the relevant government or regulatory authorities in the People's Republic of China will be completed in accordance with the applicable laws and regulations. The full text of the amended Articles of Association is available on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.metistechbio.com).

The Articles of Association and its amendments were prepared in Chinese, without formal English version. As such, the English translation shall be for reference only. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board
Metis TechBio Co., Ltd.
Tsai-Ta Lai
Chairman of the Board, executive Director and chief executive officer

Hong Kong, June 10, 2026

As at the date of this announcement, the Directors are: (i) Dr. Tsai-Ta Lai, Dr. Hongming Chen and Dr. Wenshou Wang as executive Directors; (ii) Mr. Hantao Huang and Ms. Yuan Gong as non-executive Directors; and (iii) Mr. Frank Yee Chon Lyn, Dr. Jin Li and Dr. Peter Edward Lobie as independent non-executive Directors.